Novartis Finance SA, established in 1996 and based in Switzerland, operates as a financing arm of Novartis AG, focusing on managing the company’s funding and financial strategies. The company provides services such as treasury management, debt issuance, and structured finance, supporting the broader objectives of its parent organization, which specializes in pharmaceuticals and healthcare.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| NOVNVX 0.00% 2028-09-23 EURNovartis Finance SA | Luxembourg | 2028-09-23 | 0.000 | 2.43 |
| NOVNVX 0.63% 2028-09-20 EURNovartis Finance SA | Luxembourg | 2028-09-20 | 0.625 | 2.38 |
| NOVNVX 1.13% 2027-09-30 EURNovartis Finance SA | Luxembourg | 2027-09-30 | 1.125 | 2.28 |
| NOVNVX 1.38% 2030-08-14 EURNovartis Finance SA | Luxembourg | 2030-08-14 | 1.375 | 2.67 |
| NOVNVX 1.63% 2026-11-09 EURNovartis Finance SA | Luxembourg | 2026-11-09 | 1.625 | 2.21 |
| NOVNVX 1.70% 2038-08-14 EURNovartis Finance SA | Luxembourg | 2038-08-14 | 1.700 | 3.43 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Novartis Finance SA has actively participated in the capital markets, issuing bonds to support its funding needs and optimize its capital structure. It first entered the bond market shortly after its formation, with significant issuances including a €3 billion bond program launched in 2020, which offered investors attractive yields compared to industry benchmarks. The company's bonds often showcase features such as fixed and floating rates, and they have attracted attention for their credit quality and liquidity, reflecting Novartis’s strong financial standing and strategic foresight during corporate actions.